Literature DB >> 14652673

[Follicle centre lymphoma: treatment results for stage I and II].

Holger Neumann1, Hilpert Blanck, Rainer Koch, Steffen Fiedler, Aquina Lesche, Thomas Herrmann.   

Abstract

PURPOSE: Radiotherapy is a curative treatment modality in the early stages of follicle centre lymphoma. Survival rates, patterns of failure and prognostic factors were evaluated in a retrospective analysis. PATIENTS AND METHODS: 116 patients with follicle centre lymphoma stage I and II were treated between 1970 and 1999 in Dresden. Therapy modalities were radiotherapy alone (103 patients) or combined radiotherapy/chemotherapy (13 patients). Radiotherapy was applied as involved-field-(IFI)- (104 patients), extended-field- (nine patients) or total-nodal- (three patients) irradiation. Patients received doses between 25 Gy and 50 Gy (median 35 Gy).
RESULTS: The 5- and 10-year actuarial overall survival rates were 76% and 51%. Relapse free survival was 62% and 48% respectively. The median follow-up was 4,0 years. Relapses after complete remission were registered in 44 cases. Six patients have had in-field-recurrences. The majority of out-field-recurrences were nodal relapses (50%). 11% of relapses occurred outside of lymph nodes or were disseminated failures (18%). Significant favorable prognostic factors identified by multivariate and univariate analysis were low age (age < 50 years vs. age > 50 years), low stage and performance of bipedal lymphangiography as primary staging procedure.
CONCLUSIONS: Radiotherapy is an effective and tolerable treatment modality for follicle centre lymphoma in the early stages I and II. We registered a high proportion of nodal recurrences, which may be minimized by prophylactic extended radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14652673     DOI: 10.1007/s00066-003-1025-0

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  7 in total

Review 1.  Nodal follicular lymphoma: the role of radiotherapy for stages I and II.

Authors:  Frank Heinzelmann; Marianne Engelhard; Hellmut Ottinger; Michael Bamberg; Martin Weinmann
Journal:  Strahlenther Onkol       Date:  2010-03-26       Impact factor: 3.621

2.  Radiotherapy in stage I-III follicular non-Hodgkin lymphoma. Retrospective analysis of a series of 50 patients.

Authors:  K Fakhrian; S Klemm; U Keller; C Bayer; W Riedl; M Molls; H Geinitz
Journal:  Strahlenther Onkol       Date:  2012-02-16       Impact factor: 3.621

3.  Feasibility and toxicity of concomitant radio/immunotherapy with MabThera (Rituximab®) for patients with non-Hodkin's Lymphoma: results of a prospective phase I/II study.

Authors:  Alfred Haidenberger; Sabine Fromm-Haidenberger; Alexander de Vries; Bela-Andre Popper; Michael Steurer; Ira Skvortsova; Johanna Kantner; Eberhard Gunsilius; Peter Lukas
Journal:  Strahlenther Onkol       Date:  2011-04-26       Impact factor: 3.621

4.  Long-term outcome and prognostic factors in early-stage nodal low-grade non-hodgkin's lymphomas treated with radiation therapy.

Authors:  Hans Theodor Eich; Martina Heimann; Hartmut Stützer; Jan Kriz; Marcel Reiser; Rolf-Peter Müller
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

Review 5.  Limited Stage Follicular Lymphoma: Current Role of Radiation Therapy.

Authors:  Andrea Riccardo Filippi; Patrizia Ciammella; Umberto Ricardi
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-09-01       Impact factor: 2.576

6.  Early stage W.H.O. grade I and II follicular lymphoma treated with radiation therapy alone.

Authors:  Naseer Ahmed; Timothy E Owen; Morel Rubinger; Gaynor Williams; Zoann Nugent; Shahida Ahmed; Andrew Cooke
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

7.  Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma.

Authors:  Laila König; Klaus Herfarth; Juliane Hörner-Rieber; Sascha Dietrich; Thomas Wiegel; Jürgen Debus; Andreas Viardot
Journal:  Strahlenther Onkol       Date:  2020-05-06       Impact factor: 3.621

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.